Last reviewed · How we verify
Episcleral Celecoxib
Episcleral Celecoxib is a Small molecule drug developed by Targeted Therapy Technologies, LLC. It is currently in Phase 1 development. Also known as: Sustained Release Transscleral Celecoxib.
At a glance
| Generic name | Episcleral Celecoxib |
|---|---|
| Also known as | Sustained Release Transscleral Celecoxib |
| Sponsor | Targeted Therapy Technologies, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Episcleral Celecoxib CI brief — competitive landscape report
- Episcleral Celecoxib updates RSS · CI watch RSS
- Targeted Therapy Technologies, LLC portfolio CI
Frequently asked questions about Episcleral Celecoxib
What is Episcleral Celecoxib?
Episcleral Celecoxib is a Small molecule drug developed by Targeted Therapy Technologies, LLC.
Who makes Episcleral Celecoxib?
Episcleral Celecoxib is developed by Targeted Therapy Technologies, LLC (see full Targeted Therapy Technologies, LLC pipeline at /company/targeted-therapy-technologies-llc).
Is Episcleral Celecoxib also known as anything else?
Episcleral Celecoxib is also known as Sustained Release Transscleral Celecoxib.
What development phase is Episcleral Celecoxib in?
Episcleral Celecoxib is in Phase 1.
Related
- Manufacturer: Targeted Therapy Technologies, LLC — full pipeline
- Also known as: Sustained Release Transscleral Celecoxib